Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.93 and traded as high as $2.42. Microbot Medical shares last traded at $2.36, with a volume of 967,058 shares trading hands.
Analysts Set New Price Targets
MBOT has been the topic of several recent research reports. Wall Street Zen upgraded Microbot Medical from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a research note on Thursday, April 10th.
Check Out Our Latest Stock Report on Microbot Medical
Microbot Medical Price Performance
The company has a market capitalization of $89.31 million, a PE ratio of -3.78 and a beta of 1.14. The business's 50 day simple moving average is $2.53 and its 200 day simple moving average is $1.94.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. As a group, analysts anticipate that Microbot Medical Inc. will post -0.71 EPS for the current year.
Institutional Trading of Microbot Medical
A number of hedge funds and other institutional investors have recently modified their holdings of MBOT. Renaissance Technologies LLC acquired a new stake in Microbot Medical in the 4th quarter valued at approximately $118,000. Geode Capital Management LLC grew its position in Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 10,442 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Microbot Medical during the first quarter worth about $57,000. Finally, Virtu Financial LLC acquired a new position in shares of Microbot Medical in the first quarter valued at approximately $42,000. 16.30% of the stock is owned by institutional investors and hedge funds.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Stories
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
